Assembly Biosciences, Inc. (NASDAQ: ASMB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 46.07 | EPS (ttm) | 0.55 | Insider Own | - | Shs Outstand | 19.82M | Perf Week | -16.81% |
| Market Cap | 502.17M | Forward P/E | - | EPS next Y | -3.05 | Insider Trans | -0.00% | Shs Float | 12.47M | Perf Month | -21.13% |
| Enterprise Value | 184.17M | PEG | - | EPS next Q | -0.65 | Inst Own | - | Short Float | 17.01% | Perf Quarter | 4.93% |
| Income | 0.00 | P/S | 6.79 | EPS this Y | -210.58% | Inst Trans | - | Short Ratio | 8.94 | Perf Half Y | -7.92% |
| Sales | 74.00M | P/B | 1.64 | EPS next Y | -401.32% | ROA | -0.01% | Short Interest | 2.12M | Perf YTD | -25.49% |
| Book/sh | 15.44 | P/C | 1.57 | EPS next 5Y | - | ROE | -0.02% | 52W High | 39.71 -36.19% | Perf Year | 23.31% |
| Cash/sh | 16.15 | P/FCF | - | EPS past 3/5Y | - | ROIC | -2.86% | 52W Low | 20.23 25.26% | Perf 3Y | 124.65% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - -1.84% | Gross Margin | 77.73% | Volatility | 7.61% 5.61% | Perf 5Y | -32.75% |
| Dividend TTM | - | EV/Sales | 2.49 | EPS Y/Y TTM | 108.22% | Oper. Margin | -11.76% | ATR (14) | 1.92 | Perf 10Y | -67.16% |
| Dividend Ex-Date | - | Quick Ratio | 13.99 | Sales Y/Y TTM | 155.17% | Profit Margin | -0.06% | RSI (14) | 31.01 | Recom | 2.45 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.99 | EPS Q/Q | 84.96% | SMA20 | -22.67% | Beta | 1.13 | Target Price | 51.67 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 30.00% | SMA50 | -13.88% | Rel Volume | 1.37 | Prev Close | 25.48 |
| Employees | 73 | LT Debt/Eq | 0.01 | Earnings | Nov 09 | SMA200 | -12.57% | Avg Volume | 266.39K | Price | 25.34 |
| IPO Date | Dec 17, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 72.38% 55.53% | Net Debt/EBITDA | -440.24 | Volume | 364,770 | Change | -0.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-01-26 | Reiterated | UBS | $52 | |
| Sep-01-26 | Reiterated | Mizuho | Outperform | $45 → $53 |
| Aug-18-26 | Reiterated | HC Wainwright & Co. | Buy | $50 |
| Jun-15-26 | Reiterated | Mizuho | Outperform | $40 → $45 |
| Nov-20-25 | Reiterated | Mizuho | Outperform | $36 → $40 |
| Sep-24-25 | Initiated | Citizens JMP | Outperform | $38 |
| Sep-24-24 | Reiterated | Mizuho Securities | Buy | $36 |
| Sep-20-24 | Reiterated | Jefferies | Hold | $35 |
| Oct-23-22 | Downgrade | Truist Securities | Buy → Hold | |
| Sep-01-21 | Downgrade | William Blair | Outperform → Market Perform |
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 74 | 72 | 29 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 17 | 0 | 56 | — | — | — | — | — | — | |
| Gross Profit | 57 | 72 | -27 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 20 | 20 | 18 | — | — | — | — | — | — | |
| Research and Development | 64 | 65 | 56 | — | — | — | — | — | — | |
| Other Operating Expense | -16 | -1 | -56 | — | — | — | — | — | — | |
| Operating Income | -8 | -12 | -45 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 6 | 6 | — | — | — | — | — | — | |
| Net Income Before Taxes | 0 | -6 | -40 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 0 | -6 | -40 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 0 | -6 | -40 | — | — | — | — | — | — | |
| Net Income | 0 | -6 | -40 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.55 | -0.55 | -6.69 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.55 | -0.55 | -6.69 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.55 | -0.55 | -6.69 | — | — | — | — | — | — | |
| EBITDA | 0 | -6 | -40 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 46.07 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.51 | 5.20 | 3.26 | — | — | — | — | — | — | |
| Gross Margin | 77.03 | 100.00 | -93.10 | — | — | — | — | — | — | |
| Operating Margin | -10.81 | -16.67 | -155.17 | — | — | — | — | — | — | |
| Net Margin | 0.00 | -8.33 | -137.93 | — | — | — | — | — | — | |
| Shares Outstanding | 19 | 11 | 6 | — | — | — | — | — | — | |
| Market Capitalization | 481 | 374 | 95 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | Jun 17 '26 | Sale | 23.25 | 29 | 674 | 14,560 | Jun 18 |
| White Nicole S | Chief Manufacturing Officer | Mar 30 '26 | Sale | 26.69 | 197 | 5,257 | 37,477 | Mar 31 |
| Bjorkquist Jeanette M | PFO and PAO | Mar 30 '26 | Sale | 26.69 | 328 | 8,755 | 11,089 | Mar 31 |
| GILEAD SCIENCES, INC. | 10% Owner | Aug 08 '25 | Buy | 10.80 | 4,591,840 | 49,594,168 | 4,505,391 | Oct 03 |
| McHutchison John G | Director | Mar 31 '25 | Sale | 9.85 | 757 | 7,455 | 18,347 | Apr 15 |
| Okazaki Jason A | CEO and President | Mar 31 '25 | Sale | 9.85 | 355 | 3,496 | 14,757 | Apr 01 |
| Bjorkquist Jeanette M | Principal Accounting Officer | Mar 31 '25 | Sale | 9.85 | 180 | 1,773 | 4,617 | Apr 01 |
| White Nicole S | Chief Manufacturing Officer | Mar 31 '25 | Sale | 9.85 | 197 | 1,940 | 11,674 | Apr 01 |
| Houghton Michael | Director | Dec 30 '24 | Buy | 15.61 | 3,202 | 49,998 | 3,202 | Dec 31 |
| GILEAD SCIENCES, INC. | 10% Owner | Dec 19 '24 | Buy | 21.37 | 940,499 | 20,098,464 | 2,209,471 | Dec 23 |
| Schornstein Alexander | 10% Owner | Nov 25 '24 | Buy | 14.91 | 7,976 | 118,890 | 728,113 | Nov 26 |
| Schornstein Alexander | 10% Owner | Nov 22 '24 | Buy | 14.87 | 17,024 | 253,104 | 720,137 | Nov 26 |
| White Nicole S | Chief Manufacturing Officer | Nov 18 '24 | Sale | 16.29 | 40 | 652 | 11,871 | Nov 19 |
| Schornstein Alexander | 10% Owner | Oct 08 '24 | Buy | 14.58 | 10,000 | 145,800 | 703,113 | Oct 09 |
| Okazaki Jason A | CEO and President | Oct 03 '24 | Sale | 14.81 | 197 | 2,918 | 14,904 | Oct 04 |